We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
Published online by Cambridge University Press: 23 March 2020
Schizophrenia still ranks among the first 10 leading causes of disability worldwide. Recent analyses show that there is a considerable treatment gap in schizophrenia in Europe and worldwide.
To provide evidence-based information and give a concise overview of what is needed to overcome the treatment gap in schizophrenia.
Using a combined approach of systematic review and health economics was used to assess the socioeconomic impact of medical interventions (or the lack of thereof) for schizophrenia.
The case study analysis demonstrates socioeconomic impact and health gains of best practices in specific healthcare interventions for schizophrenia in comparison with the cost burden of current care or non-treatment.
Unterstützung bei Symposien/Symposia Support
– Janssen-Cilag GmbH, Neuss
– Aristo Pharma GmbH, Berlin
– Lilly Deutschland GmbH, Bad Homburg
– Servier Deutschland GmbH, München
– Fakultätsmitglied/Faculty Member
– Lundbeck International Neuroscience Foundation (LINF), Dänemark
You have
Access
Comments
No Comments have been published for this article.